Cite
HARVARD Citation
Embleton, A. et al. (n.d.). 2748 Assessment of associations between disease stage and toxicity with bevacizumab (BEV) in ICON7, a phase III trial of front-line carboplatin/paclitaxel (CP) ± BEV for ovarian cancer (OC). European journal of cancer. pp. S546-. [Online].